8-KEarnings & ResultsExhibits & Filings

REGENERON PHARMACEUTICALS, INC. 8-K Report, Financial Results (May 4, 2023)

Filed May 4, 2023For Securities:REGN

Summary

Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on May 4, 2023, to announce its first-quarter 2023 financial and operating results via a press release. While the 8-K itself is brief and primarily serves to incorporate the press release, the key investor information lies within that furnished document. Investors should review the press release for details on revenue, earnings, product performance, and any forward-looking statements or strategic updates from the company during the first quarter of 2023. This filing indicates that the company met its reporting obligations by providing timely financial updates. The press release, incorporated by reference, will contain the specifics regarding the company's performance, including key metrics for its approved products and pipeline developments. Investors interested in Regeneron's performance should look to the details within the press release for a comprehensive understanding of the quarter's outcomes and management's commentary.

Key Highlights

  • 1Regeneron Pharmaceuticals (REGN) announced its Q1 2023 financial and operating results.
  • 2The results were disclosed via a press release filed as Exhibit 99.1 to the 8-K.
  • 3The 8-K filing itself does not contain the detailed financial results but incorporates them by reference.
  • 4Investors need to access the furnished press release (Exhibit 99.1) for the specific financial and operational data.
  • 5The filing date of the 8-K is May 4, 2023, with the event date (announcement) being May 3, 2023.
  • 6The information furnished is not considered 'filed' for Section 18 purposes unless specifically incorporated into a registration statement.

Frequently Asked Questions

The detailed financial and operating results for the first quarter of 2023 are provided in the press release (Exhibit 99.1) that was furnished with this 8-K filing on May 4, 2023. You will need to review that press release for specific figures.

This 8-K filing is significant as it officially announces and provides access to Regeneron's latest quarterly financial and operational performance. It ensures that this information is publicly available and signals the company's adherence to timely disclosure requirements.

No, the 8-K filing itself does not contain the detailed Q1 2023 earnings numbers. It serves as a notification and incorporates by reference the press release where these details are fully disclosed.

The statement that the information is not deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934 means that statements made within the furnished press release (unless expressly incorporated into another filing) do not carry the same legal liability as information that is formally filed with the SEC under Section 18. However, it is still considered important information for investors.